New DCVax-L brain cancer vaccine trial starts enrolling

Tools

Another site in the U.S., Hoag Memorial Hospital Presbyterian in Orange County, CA, has begun recruiting for a Phase II clinical trial of Northwest Biotherapeutics' ($NWBO) DCVax-L personalized brain cancer vaccine for the treatment of glioblastoma multiforme, the most aggressive and lethal form of brain cancer. By the end of February 2012, Northwest Biotherapeutics had 30 sites open and recruiting in the U.S., and the company plans for 40 by the end of the second quarter. DCVax-L is made from the patient's blood and tumor tissue. In January 2011, FierceVaccines reported that Northwest Biotherapeutics had restarted recruitment into Phase II trials after a two-year postponement, because of the company's cash issues. Press release

Comments